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Abstract:  
Introduction: Increasing evidence suggests that poor lung function in adulthood is determined 
very early in life. Our study aims were: (1) identify factors associated with early infant lung 
function; (2) quantify the link between early infant lung function and early adult lung 
function; (3) identify environmental and inherited factors which predict lung function 
throughout the post-natal growth period.  
Methods: In this longitudinal study, 253 individuals were recruited antenatally. Lung function 
and allergy testing occurred at 1, 6, 12 months, 6, 11, 18 and 24 years of age. The relationship 
between lung function at 1 month (V’maxFRC) and spirometry variables at each follow-up 
was evaluated. Early life predictors of spirometry were assessed longitudinally using linear 
mixed models. 
Results: V’maxFRC correlated positively with FEF25-75% at every assessment from 6 to 24 
years and FEV1/FVC at 11 and 24 years and inversely with airway responsiveness at 6 and 18 
years. Maternal asthma and smoking in pregnancy were associated with lower FEV1 from 6 to 
24 years (-99ml, p=0.03; -77ml, p=0.045 respectively). Lower V’maxFRC at 1 month was 
associated with asthma and wheeze through to 24 years.  
Conclusion: Lung airflow measurements track from birth into early adulthood, suggesting a 
permanent and stable airway framework is laid down in the antenatal period. Lower infant 
airway function is associated with respiratory symptoms into adulthood, indicating the link is 
clinically important.  Antenatal and early life exposures must be addressed in order to 
maximise airway growth and reduce lifelong respiratory compromise. 
 
 
Abbreviations:  
COPD – chronic obstructive pulmonary disease 
DRS – dose response slope 
FEF25-75% - forced expiratory flow rate between 25-75% of forced vital capacity 
FEV1 –forced expiratory volume in 1 second 
FVC – forced vital capacity 
Log – natural logarithm 
PIAF – Perth Infant Asthma Follow up study 
V’maxFRC – Maximum flow rate at functional residual capacity 
  
Introduction: 
The lungs mature throughout life, from development of the lung architecture in utero, airway 
and parenchymal growth in childhood and adolescence, through to degenerative changes 
during adulthood. Spirometry is a surrogate measure of both airway calibre and lung growth 
and the changes in the development of these with age are reflected in lung function testing 1. 
Increasing evidence shows that determinants of poor lung function and respiratory disease in 
adulthood are active in very early life 2-7. 
Both males and females reach their peak lung function in early adulthood, making this an ideal 
time to assess total lung growth 1. The antenatal, early life and genetic factors that affect this 
peak in lung function will likely impact on function through to late adulthood. Reduced lung 
function in early adulthood is associated with chronic obstructive pulmonary disease (COPD) 
in later life8, emphasising the importance of attaining maximum lung growth prior to the 
inevitable decline. Identifying in utero, genetic and environmental factors which affect growth 
in lung function from early infancy, throughout childhood and into adulthood, has the potential 
to lead to interventions that ensure maximum lung growth is attained, thus leading to improved 
lifelong lung health. 
In the Tucson longitudinal respiratory birth cohort study, those with low lung function in 
infancy continued to have low lung function into adulthood 9. Despite the importance of this 
finding, the study’s results have not been replicated given the several decades of follow-up 
necessary and the difficulties in performing infant lung function testing which was a relatively 
new technique 30 years ago 9.  
In our cohort, infants’ lung function was studied very early, at one month of age when minimal 
effect of post-natal exposures would be expected, and was repeated during infancy at 6 and 12 
months. Spirometry was performed by the cohort at follow-up assessments every 6 years 
between the ages of 6 and 24 years of age. We hypothesised that both lung function at one 
month and post-natal environmental exposures are important in determining the peak lung 
function reached by young adults.  The aims of our study were to (1) identify the factors 
associated with lung function measured soon after birth, (2) assess the link between lung 
function at 1 month of age and lung function in early adulthood and (3) identify environmental 
and inherited factors that predict lung function throughout the post-natal growth period, 
between 1 month and 24 years.  
 
Materials and Methods: 
The Perth Infant Asthma Follow up study (PIAF) is a longitudinal birth cohort with 253 
individuals recruited antenatally from a suburban maternity hospital between 1987 and 1990. 
There was no pre-selection based on family history of asthma or atopy. Recruitment has been 
described in detail previously.10  
These subjects have had detailed respiratory assessments at 1, 6, 12 months, 6, 11, 18 and 24 
years of age, including questionnaires, lung function, airway responsiveness and skin prick 
testing.  
Infant lung function testing at 1, 6 and 12 months of age involved rapid thoraco-abdominal 
compression during tidal breathing at the end of normal inspiration, after sleep was induced 
with oral chloral hydrate.11 V’maxFRC, the maximum flow at functional residual capacity, was 
recorded as the mean of 3-5 acceptable measurements. Infant lung function data were not 
reported as percent predicted according to our laboratory’s reference equation, as this equation 
adjusts for sex and adjusted for sex and in utero smoke exposure12.  
Spirometry, using dynamic forced expiratory flow manoeuvre at 6, 11, 18 and 24 years, 
measured forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced 
expiratory flow between 25-75% of FVC (FEF25-75%) and FEV1/FVC 
13.  
Airway responsiveness was assessed at 1 month of age with a histamine challenge using hand-
held glass dosimeters and the Yan technique 14. Increasing concentrations of histamine were 
inhaled until a drop in V’maxFRC of 40% was reached, signifying a positive test. Those with 
a negative airway responsiveness challenge did not reach a 40% drop in V’maxFRC despite 
inhaling the maximum cumulative dose of 7.8 μmol of histamine. The dose response slope 
(DRS) is the maximum percentage drop in V’maxFRC divided by the cumulative dose of 
inhaled histamine 15.  
Skin prick testing was carried out at 1, 6 and 12 months of age to rye grass pollen, cow’s milk, 
egg white, Dermatophagoides pteronyssinus and D. farinae 16,17.   A mean wheal diameter of 
≥3mm greater than the control was recorded as positive. Only those with a positive result or 
those who were assessed at all three time points (n=179) were included in the analysis, as a 
positive test could not be ruled out otherwise. 
Antenatal and infant questionnaires were completed by one or both parents at each assessment 
and included: questions regarding current and previous smoking history and current and 
previous feeding history including breastfeeding history and timing of introduction of 
breastmilk substitute formula. Only those with complete feeding history were included in the 
analysis of breastfeeding (n=181). 
Questionnaires from 6 years of age were completed by the parent or participant as appropriate. 
Recent wheeze at each assessment was defined by symptoms in the previous 12 months. 
Current asthma at each assessment was defined by a physician diagnosis, plus symptoms or 
asthma medications within the previous 12 months.  
Predictive variables were chosen based on known associations with lung function in infancy or 
childhood and included: sex; exposure to tobacco smoke in utero; parental history of asthma; 
birthweight; exclusive breastfeeding the first three months in infancy; infant atopy (a positive 
skin prick testing at 1, 6 or 12 months of age); physician diagnosis asthma during childhood; 
smoking. 
The study was approved by the Princess Margaret Hospital for Children Ethics Committee 
(2054EP). Parents or subjects when appropriate, signed informed consent forms for each 
assessment. 
Statistics 
Factors associated with V’maxFRC at 1 month were identified using the General Linear Model. 
Each potential factor was entered into the model separately. Infant length at time of assessment 
was included and the mean V’maxFRC for each group was standardised to the mean length of 
the infants. All significant variables from the univariate model were then included in a multi-
variate model, including interaction terms. 
The association between lung function at 1 month and at subsequent follow-ups was assessed 
with Pearson’s correlation (r) or Spearman’s correlation () for non-parametric variables. R2 
estimated the % variability in spirometry measurements accounted for by infant lung function. 
V’maxFRC at 1 month was log transformed (base e) to approach a normal distribution and then 
adjusted for concurrent length. Dose response slope from histamine challenge was also log 
transformed.  Spirometry variables were adjusted for sex and concurrent height at each 
assessment.  
Linear mixed models were used to assess the link between early life factors and spirometry 
outcomes longitudinally, in the context of known infant lung function, using unstructured 
covariance. Spirometry variables from each assessment at 6, 11, 18 and 24 years were included 
in the model. Time-dependent factors, age and height at each assessment, were included in the 
model and sex was included as a time-independent factor. Each predictive variable was entered 
into the model separately and then significant factors were all included in a multi-variate model. 
V’maxFRC was again logarithmically transformed and adjusted for length. 
Lung function at 1 month of age as a predictor of recent wheeze and current asthma at each 
follow-up was assessed with logistic regression and odds ratios are reported. Post-hoc analysis 
included current atopy as a co-factor in the model, as defined by positive skin prick test. 
V’maxFRC at 1 month was log transformed, adjusted for length and divided into two groups, 
about the median. Mean spirometry variables at each assessment were calculated for these two 
groups, having adjusted for concurrent height, age and sex and standardised to the mean height 
and age, using a general linear model. This is portrayed graphically. 
A 2-sided p value <0·05 was used to define statistical significance. Statistical analyses were 
performed using IBM SPSS Statistics for Windows, version 24·0·0 (Released 2016, Armonk, 
NY: IBM Corp.) 
  
Results: 
Baseline Data  
Of the original cohort, 242 participants had infant lung function testing at 1 month of age, 195 
at 6 months and 165 at 12 months. Of those assessed at 1 month, 190 were seen for follow up 
at least once at 6, 11, 18 or 24 years and were included in longitudinal analysis. Participation 
numbers and characteristics at each follow up have been presented previously 24. There was 
less maternal in utero smoke exposure in the group seen at 18 and 24 years (25%), than in the 
original cohort (32%). Unadjusted baseline spirometry at each assessment is presented in 
supplementary table 1. 
Lung function during infancy 
Mean V’maxFRC doubled in the first year of life from 98.9 ml/sec (SD 49.6) at 1 month, to 
157.2 ml/sec (SD 71) at 6 months and 200.1 ml/sec (SD 82.8) at 12 months of age.  Lung 
growth tracked throughout infancy with a strong correlation between V’maxFRC at 1 month 
and 6 months (=0.55, p<0.001) and V’maxFRC at 6 months and 12 months of age (=0.45, 
p<0.001). 
 
Predictors of lung function at 1 month of age 
Male gender was associated with lower lung function at 1 month of age (mean V’maxFRC: 
males 92.0 ml/sec and females 107·3 ml/sec, p=0·019). Exposure to maternal tobacco smoke 
in utero was associated with lower infant lung function at 1 month (mean V’maxFRC: 89·4 
ml/sec if exposed and 104·4 ml/sec if not exposed, p=0·027). Birthweight, parental asthma, 
paternal smoking during the pregnancy and infant atopy were not associated with a significant 
difference in lung function at 1 month of age (table 1). 
In the multivariate model, sex (p=0·044) and maternal in utero smoking (p=0·022) were 
independently associated with V’maxFRC at 1 month of age. There was no significant 
interaction effect between sex and maternal smoking on infant lung function (p=0·576). 
 
Tracking of lung function from 1 month to 24 years  
V’maxFRC at 1 month correlated with FEF25-75% at each assessment from 6 to 24 years and 
with FEV1/FVC at 11 and 24 years (supplementary table 2). R
2 ranged from 0·03 to 0·08, thus 
V’maxFRC at 1 month accounted for up to 8% of the variability in FEF 25-75% and FEV1/FVC 
at each follow up assessment.  
V’maxFRC was inversely correlated with airway responsiveness, as measured by the dose 
response slope in histamine challenge, at 6 and 18 years (r = -0·25 p=0·013 and r = -0·22 
p=0·016 respectively. Supplementary table 2).  
 
 
 
Infant airway responsiveness and spirometry at each follow up 
Infant airway responsiveness at 1 month of age, as measured by the DRS to histamine 
challenge, was significantly correlated with FEV1 and FVC at 6 years of age (r=-0.225, 
p=0.039; r=-0.338, p=0.002 respectively), but not at further assessments between 11 and 24 
years of age. There was no link between V’maxFRC and DRS at 1 month (supplementary table 
3). 
 
 Longitudinal analysis of lung function  
Amongst those with infant lung function measurements at 1 month of age, 190 participants had 
525 follow-up lung function assessments at 6, 11, 18 and/or 24 years. In longitudinal analysis, 
V’maxFRC at 1 month was positively associated with FEF25-75% and FEV1/FVC from 6-24 
years. Exposure to maternal smoking in utero was associated with lower FEV1 from 6-24 years 
compared with those not exposed (mean difference -0·085 L, p=0·048). A history of physician 
diagnosed asthma was associated with lower FEV1/FVC from 6 to 24 years compared with 
those with no history of asthma (mean difference -3·1%, p=0·001). A positive skin prick test 
in the first year was associated with lower FEV1, FEF25-75% and FEV1/FVC from 6 to 24 
years compared with those with no positive skin prick tests during infancy (mean difference -
0.138L p=0·018, -0·298 L/s p=0·006 L/s and -2·3% p=0·034, respectively). Current tobacco 
smoking at 24 years of age was not associated with any lung function variable from 6 to 24 to 
years. Table 2.  
Only variables with a significant relationship in the univariate analysis (p<0·05) were included 
in multivariate analysis. V’maxFRC at 1 month was associated with FEF25-75% from 6 to 24 
years in the multivariate analysis and infant atopy was associated with FEV1, FEF 25-75% and 
FEV1/FVC from 6 to 24 years (table 3). 
 
Longitudinal lung function and V’maxFRC below and above median 
Using Linear Mixed Models, including sex, age and height in the model, V’maxFRC above the 
median at 1 month was associated with significantly higher FEF25-75% from 6 to 24 years 
(mean difference 0·22L/s, p=0·001) and FEV1/FVC longitudinally from 6-24 years (mean 
difference 2.46%  p=0·002). There was no significant association with FEV1 or FVC. The mean 
lung function at each assessment are depicted in figure 1.  
 
V’maxFRC predicts wheeze and asthma 
Participants with a V’maxFRC below the median at 1 month of age were more likely to have 
had recent wheeze within the previous 12 months at 6, 11 and 24 years, than those with 
V’maxFRC above the median.  
Participants with a V’maxFRC below the median at 1 month of age were more likely to have 
asthma in the previous 12 months at 18 and 24 years, than those with V’maxFRC above the 
median (table 4). These associations remained significant when adjusted for current atopy (OR 
=4·3, p=0·013 at 18 years and OR =5·5, p=0·009 at 24 years). 
 
  
Discussion: 
 
Our study establishes that the principal influence of impaired infant lung function on 
respiratory function in early adulthood is on airflow, as measured by FEV1/FVC and FEF25-
75%, rather than overall lung size, as measured by FEV1 and FVC.  We have also demonstrated 
that low lung function in early infancy is associated with respiratory symptoms throughout 
childhood and into early adulthood. The clearly separate relationships between infant 
V’maxFRC (a flow-related variable) and flow-related spirometric variables in adulthood, as 
opposed to variables more greatly influenced by lung size, have not been previously 
demonstrated. There is likely a causal relationship between the development of relatively 
abnormal airway physiology antenatally and the clinical outcomes related to airway calibre, 
wheeze and asthma, which persist throughout the post-natal lung growth period. 
 
Our findings are in line with prior reports, including those from the Tucson Children’s 
Respiratory Study 9, that have found infant lung function to be related to reduced lung function 
in early adulthood, however previous studies did not demonstrate an association specifically 
with variables that reflect airway function. Infant lung function in our cohort was measured in 
a larger number of subjects and closer to birth with a tightly controlled age and hence less likely 
to be influenced by environmental factors. Physiologically, the strength of our current data, 
when considered alongside data from previous analyses9,18, suggest that future airway structure 
is laid down in the antenatal period, but that this is separate from the potential for lung growth, 
which is also known to be influenced by antenatal and early life exposures.  
 
V’maxFRC at 1 month of age was inversely associated with airway responsiveness at 6 and 18 
years. That is, those with higher lung function in infancy, had lower airway responsiveness 
later on and vice versa. Increased airway responsiveness, sensitivity of the airways, is one of 
the hallmarks of asthma and correlates with symptom severity. Airway responsiveness is 
related to inflammation of the lower airways19 and airway inflammation is associated with 
reduced airflow.  As we did not take airway samples, we could not assess for the presence or 
degree of airway inflammation. A previous publication from the 6 year follow-up of the PIAF 
cohort, showed that increased airway responsiveness during infancy was associated with lower 
lung function in early childhood20. However in subsequent assessments, this association is no 
longer seen, suggesting that infant airway responsiveness and the presumed underlying 
inflammation, is not a permanent change. 
 
A number of factors were identified which were associated with lung function at just 1 month 
of age. Exposure to maternal in utero tobacco smoking and male gender were both 
independently associated with lower V’maxFRC at 1 month. These findings have previously 
been reported in the PIAF cohort, albeit when looking at repeated measurements throughout 
the first year of life, as well as in studies by other groups 12,21,22. We assume that lung function 
at 1 month of age is reflective of antenatal growth. Only term infants were included and this 
first assessment was performed before the infants’ had any significant respiratory illnesses but 
there would have been some environmental exposures, such as exposure to tobacco smoke in 
the home, feeding (breastmilk versus formula) and aeroallergen exposure (house dust mite, 
animal dander, pollens etc.), which could potentially have had some impact on lung function 
in the neonatal period. 
In utero tobacco smoke exposure was associated with lower infant lung function at 1 month of 
age as well as lower FEV1 throughout childhood up to early adulthood. This subtle deficit, 
mean 77ml, may be of long-term clinical significance given that a lower FEV1 in early 
adulthood is associated with increased risk of COPD as well as all-cause mortality23,24.  
In this cohort, those with a history of asthma during childhood had persistently lower 
FEV1/FVC throughout childhood up to early adulthood, while a history of maternal asthma 
was associated with lower FEV1. Asthma in early adulthood is associated with lower infant 
lung function at 1 month and reduced flow throughout childhood 25. Low FEV1/FVC is a 
defining criteria of COPD and these results support the hypothesis that childhood asthma is a 
risk factor for COPD26. The association between early atopy and lower lung function from 
infancy into early adulthood has previously been reported in this cohort18,25. The effect of 
children smoking tobacco themselves during childhood and adolescence on lung function was 
not addressed in this study, as parents were present at the assessments up until 18 years of age 
and thus a truthful answer could not be assumed. Therefore only tobacco smoking at 24 years 
was included in the model and so we are unable to comment on the effect of self-smoking on 
the developing lung. 
 
This study has a number of limitations which are inevitable due to the length of follow up. 
Firstly, the technique for measuring infant lung function which was used in this study is based 
on the tidal volume range and was the standard in the late 1980s when this study began. This 
technique has since been adapted to more closely mimic spirometry using raised volume 27,28. 
However, we still found significant correlations between the infant lung function measurement, 
V’maxFRC and spirometry variables, particularly FEF25-75%, which is also a measure of 
airflow at low lung volume. Total infant lung capacity measurements would have been 
interesting, but measuring this in addition to the technique used would have been impractical. 
Furthermore, infant lung function testing is a very labour and time intensive procedure, making 
the recruitment of large cohorts almost impossible. Given that this study has spanned almost 
three decades, a loss to follow up is not unexpected. Perth, Western Australia is a particularly 
isolated city and many young people travel for work, college or leisure in their early adult 
years, which may have contributed to the difficulty in retaining participation. By using mixed 
models, we were able to compensate for missing values in those who had multiple follow ups. 
Another limitation to note is that lung function was performed without bronchodilator 
responsiveness, therefore reversibility was not assessed. However in another longitudinal 
respiratory birth cohort study, there was no significant difference in relationships between pre 
and post bronchodilator values at follow ups and infant lung function9.   
 
Lung airflow measurements track from soon after birth into early adulthood, indicating a 
permanent and stable airway framework, which is laid down in the antenatal period. Lower 
airway function in infancy is associated with respiratory symptoms through into adulthood, 
signifying a clinically significant effect.  Antenatal factors, particularly tobacco smoke 
exposure, must continue to be addressed in order to maximise lung function into early 
adulthood and thus reduce the risk for lifelong respiratory compromise. 
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Table 1. Factors associated with lung function at 1 month of age: Univariate model 
  N Mean V’maxFRC 
ml/sec 
95%CI p value 
Sex   Male 134 91·98 83·52 – 100·45 0.019 
 Female 
 
108 107·27 97·82 – 116·72  
Maternal Asthma No  192 98·88 91·79 – 105·98 0.96 
Yes 50 98·5 84·58 – 112·43  
      
Paternal asthma No  197 103·15 92·89 – 107·01 0.34 
Yes 34 93·75 75·92 – 109·97  
      
Maternal smoking in pregnancy No 157 104·37 96·59 -112·14 0.027 
Yes 84 89·38 78·71 – 100·05  
      
Paternal smoking in pregnancy No  141 90·1 94·76  - 111·55 0·17 
Yes 88 82·27 83·41 – 104·1  
      
Birthweight <3000g 43 85·04 69·45 – 100·64 0·276 
 3000-3500g 97 102·59 92·56 – 112·63   
 3500 –4000g 72 101·48 89·68 – 113·27  
 >4000g 27 103·22 83·72 – 112·73  
      
Early atopy No 138 103·62 94·97 – 112·27 0·093 
 Yes 31 86·26 67·9 – 104·56  
V’maxFRC at 1 month was adjusted for length and then standardised to mean length of the infants at 1 month 
(=55.1cm). 95% CI confidence intervals. Bold font indicates p<0·05. Parental asthma ever at time of 
recruitment. Parental smoking at all during the pregnancy. Early atopy -positive skin prick test in first year of 
life.  
 
Table 2. Associations with lung function longitudinally from 6 to 24 years: univariate 
analysis 
No. of subjects 
included 
(no. of assessments) 
Mean difference in  
FEV1 (L) 
(6-24 years) 
Mean difference in 
 FVC (L) 
(6-24 years) 
Mean difference in 
FEF25-75% (L/s)  
(6-24 years) 
Mean difference in 
FEV1/FVC 
(6-24 years) 
(SE) P value  (SE) P value  (SE) P value  (SE) P value 
Ln 
V’maxFRC at 
1 month 
190 
(525) 
0·01 
 (0·015) 
0·53 -0·002 
(0·029) 
0·49 0·08 
(0·03) 
0·008 0·015 
(0·004) 
<0·001 
 
Maternal 
smoking in 
pregnancy  
 
199 
(549) 
 
-0·077 
(0·038) 
 
0·045 
 
-0·109 
(0·062) 
 
0·087 
 
-0·067 
(0·064) 
 
0·293 
 
-0·0021 
(0·008) 
 
0·86 
 
Maternal 
asthma 
 
200 
(549) 
 
-0·099 
(0·045) 
 
0·03 
 
-0·078 
(0·048) 
 
0·1 
 
-0·037 
0·074 
 
0·62 
 
-0·012 
(0·009) 
 
 
0·21 
Breastfed x 
3months 
 
147 
(454) 
0·037 
(0·04) 
0·39 -0·009 
(0·065) 
0·88 0·065 
(0·076) 
0·39 0·015 
(0·01) 
0·1 
Early atopy 150 
(430) 
-0·138 
(0·055) 
0·019 -0·062 
(0·084) 
0·47 -0·25 
(0·086) 
0·004 
 
-0·023 
(0·011) 
 
0·036 
Asthma ever 145 
(450) 
0·048 
(0·052) 
0·36 0.047 
(0.035) 
0·18 -0·11 
(0·075) 
0·14 -0·031 
(0·009) 
0·001 
Tobacco 
smoker at 24 
years 
147 
(452) 
0·015 
(0·04) 
0·73 0·114 
(0·076) 
0·17 -0·019 
(0·087) 
0·83 -0·02 
(0·011) 
0·074 
Univariate analysis using linear mixed model. Mean difference in lung function associated with each factor, 
assessed longitudinally from 6-24 years. Time dependent variables age and height at each assessment and the 
time-independent variable of sex were included in the model. V’maxFRC ml/s at 1 month was log transformed 
and then adjusted for infant length. Bold font indicates p<0·05. 
Table 3: Factors associated with lung function longitudinally from 6 to 24 years: multi-
variate analysis 
 Mean difference  
FEV1 (L) 6-24 yrs 
n=150 
Mean difference  
FEF25-75% 6-24 yrs 
n=146 
Mean difference  
FEV1/FVC 6-24 yrs 
n=110 
  (SE) P value  (SE) P value (SE) P value 
Maternal smoking -0·061 
(0·041) 
0·148 - - - - 
Maternal asthma 0·084 
(0·05) 
0·1 - - - - 
V’maxFRC at 1 month - - 0·09 
(0·033) 
0·008 0·035 
(0·039) 
0·36 
Early atopy -0·125 
(0·05) 
0·015 0·218 
(0·087) 
0. ·013 -0·024 
(0·095) 
0·013 
Asthma ever - - - - -0·039 
(0·085) 
0·65 
Multi-variate analysis using linear mixed model. Mean difference in lung function associated with each factor, 
assessed longitudinally from 6-24 years.  Time dependent variables age and height at each assessment and the 
time-independent variable of sex were included in the model. V’maxFRC was log transformed and then adjusted 
for length. Only variables with p<0·05 in the univariate model were included in the multivariate model. Bold 
font indicates p<0·05 
 
  
 Table 4. Odds ratio for developing outcome at each assessment if V’maxFRC below the 
median at 1 month of age 
 6 year 
OR 
(95% CI) 
 
P value 
11 years 
OR 
(95% CI) 
 
P value 
18 years 
OR 
(95% CI) 
 
P value 
24 years 
OR 
(95% CI) 
 
P value 
 
Recent 
Wheeze* 
 
8·05 
(1·5 -10·4) 
 
0·004 
 
4·5 
(1·1 – 5·4) 
 
0·033 
 
3·1 
(0·92 -4·2) 
 
0·08 
 
2·0 
(1·09 – 4) 
 
0·047 
 
Current 
Asthma# 
 
1·6 
(0·7 -3·7) 
 
0·27 
 
1·8 
(0·8 – 4) 
 
 
0·16 
 
 
3·5 
(1·2 -10·5) 
 
0·023 
 
4·05 
(1·4 -11) 
 
0·006 
*Wheeze reported in the 12 months prior to assessment 
#Physician diagnosis of asthma with symptoms or medications in the 12 months prior to assessment 
  
Figure 1 Lung function at 6, 11, 18 and 24 years in those with V’maxFRC above and below the 
median at 1 month of age 
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Panel a. FEF 25-75%; panel b. FEV1/FVC; panel c. FEV1; panel d. FVC. 
Univariate general linear model with V’maxFRC at 1 month log transformed and then adjusted for 
length and gender. Dashed line – V’maxFRC <median at 1 month of age, solid line – V’maxFRC 
>median at 1 month of age.  
Spirometry adjusted for gender, height and age at assessment and standardised to mean age and 
height at each assessment.  
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